Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who are able to give written consent to participate
- People who have been diagnosed with Systemic Sclerosis (SSc) according to a specific set of medical classification guidelines, and who also have a positive ANA (a type of blood test result)
- People whose fatigue has been measured as moderate or above using a standard fatigue questionnaire called the FACIT-Fatigue scale (a score of 55 or higher)
- People who experience Raynaud's phenomenon (a condition where fingers or toes change colour and become painful in the cold) with a severity score at or above a certain threshold on a standard measurement tool (confirm with trial site)
- People who have been on stable, unchanged daily doses of any immunosuppressants, blood vessel-widening medications, pulmonary hypertension treatments, antidepressants, or anti-anxiety medications for at least 4 weeks before the study starts
- People who currently own and regularly use an iPhone or Android smartphone
- People who are able to attend scheduled clinic visits and follow the study procedures
Who may not be able to join:
- People who have previously had a sympathectomy or a stellate ganglion block (certain nerve procedures involving the hands or neck area)
- People who have had Botox injections into their fingers within the last 3 months
- People who have diabetes
- People who have had major surgery within the last 8 weeks
- People who have been hospitalised for any reason within 4 weeks before the study start date
- People who currently have an active cancer
- People who are pregnant or breastfeeding
- People with severely reduced kidney function (a specific blood filtration measurement below a set level) or who are on dialysis
- People with significant liver disease, defined as worse than a specific stage of liver function (confirm with trial site)
- People who are currently prescribed beta-blocker medications on a regular daily basis
- People who are currently prescribed regular daily doses of sedatives, sleeping tablets, opioid painkillers, benzodiazepines, or antipsychotic medications
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robyn T Domsic, MD, University of Pittsburgh
Phone: 412-648-7871
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in fatigue; Change in average weekly Raynaud attacks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.